PHAT NASDAQ
Florham Park, NJ 07932
US
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Parikh Asit | M-Exempt | 17,500 | $4.95 | 2026-05-20 |
| Parikh Asit | D-Return | 17,500 | $4.95 | 2026-05-20 |
| Topper James N | A-Award | 24,122 | — | 2026-05-19 |
| Stenhouse Mark | A-Award | 24,122 | — | 2026-05-19 |
| FIELDS HEIDI | A-Award | 24,122 | — | 2026-05-19 |